SB-525 Gene Therapy Phase 1/2 Trial Begins for Hemophilia A Patients

SB-525 Gene Therapy Phase 1/2 Trial Begins for Hemophilia A Patients
This post was originally published on this site

The first patient in a Phase 1/2 clinical trial (“the Alta trial”) designed to assess safety and tolerability of SB-525 gene therapy has received treatment. Sangamo, in a collaboration with Pfizer, developed  the SB-525 gene therapy to correct the Factor VIII (FVIII) defect in Hemophilia A patients.

The Alta trial (ClinicalTrials.gov Number: NCT03061201) is currently recruiting male patients, and intends to enroll 20 adult patients with severe Hemophilia A. This clinical study will assess SB-525 adverse events and the levels of circulating FVIII up to three years after SB-525 infusion.

Hemophilia A patients need to repeatedly receive FVIII blood infusions to replace defects in blood clotting Factor VIII and prevent bleeding. Now, a single SB-525 administration may enable patient’s own cells to constantly produce the same amino acid sequence used in replacement therapy (Refacto and Xyntha).

SB-525 relies on a genetically engineered virus, recombinant adeno-associated virus (rAAV), carrying a “healthy” FVIII gene construct. The rAAV is harmless for humans, but it still delivers the corrected gene to cells in tissues. SB-525 rAAV is designed to restrict FVIII gene expression to the liver, a strategy intended to increase FVIII long-term hepatic production in hemophilia A patients.

This new therapy results from a global collaboration and license agreement between Sangamo and Pfizer to develop and commercialize gene therapies for hemophilia.”We are excited to see progress in our partnership program for SB-525 with Sangamo,” said Greg LaRosa, Chief Scientific Officer, Pfizer Rare Disease in a press release issued by Sangamo . “By combining Sangamo’s scientific and technical expertise across multiple genomic platforms, with Pfizer’s global reach, resources and expertise, we are advancing the promise of gene therapy with the hope of making a meaningful impact for people living with Hemophilia A.”

Earlier this year, the U.S. Food and Drug Administration granted Orphan Drug and Fast Track designations to SB-525, which also received Orphan Medicinal Product designation from the European Medicines Agency.

The post SB-525 Gene Therapy Phase 1/2 Trial Begins for Hemophilia A Patients appeared first on Hemophilia News Today.

Chris Comish serves as the Publisher of the website, and is responsible for directing the editorial focus as well as putting the finishing touches on many featured articles.